Recently, the US Food and Drug Administration (FDA) issued a public safety alert, responding to the results of the now-published Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities (CARES) trial. The CARES trial showed no significant difference between allopurinol and febuxostat in the primary composite end point of cardiovascular (CV) events in subjects with gout and established CV comorbidities at baseline. However, there was a significantly increased risk of CV and all-cause mortality with febuxostat. Urate-lowering therapy (ULT) is central to the long-term management of gout, and xanthine oxidoreductase inhibitor (XOI) therapy is the consensus first-line approach. Allopurinol is generally the first XOI used, but febuxostat is an effective XOI option, and is commonly used when allopurinol is not tolerated. These data are further relevant since CV comorbidities are common in gout. Here, we examine why the CARES trial was done, and discuss other, ongoing comparative studies of febuxostat and allopurinol whose results are awaited. We assess the strengths and limitations of the CARES trial, and appraise the robustness and biologic plausibility of the results. The CARES trial does not prove that febuxostat raises CV mortality risk, but suggests greater risk with febuxostat than allopurinol. The CARES trial results do not support first-line use of febuxostat ULT, and raise questions about febuxostat placement at various pharmacologic ULT decision tree branches. Alternatives to febuxostat that are frequently effective include allopurinol dose escalation and uricosuric therapy alone or combined with allopurinol. The FDA safety alert highlights the need for shared ULT medical decision-making with gout patients, including discussion of the CV safety of febuxostat.
Introduction
In November 2017, the US Food and Drug Administration (FDA) issued a public safety alert concerning febuxostat for the management of hyperuricemia in gout, citing a signal for increased risk of cardiovascular (CV) and all-cause mortality (1) . This notice was in response to preliminary results of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities (CARES) clinical trial. Full CARES trial results were published in the New England Journal of Medicine in March 2018 (2) .
Urate-lowering therapy (ULT) is central to the long-term management of gout (3) (4) (5) (6) . Use of an inhibitor of the dual enzyme xanthine oxidoreductase (commonly known as xanthine oxidase) is the consensus first-line therapeutic strategy for ULT (3) (4) (5) (6) . In clinical practice, allopurinol is generally used as the first-line xanthine oxidoreductase inhibitor (XOI) in gout. The XOI febuxostat is commonly used in ULT when allopurinol is not tolerated, or when the maximum allopurinol dose chosen has not achieved lowering of the urate level to the selected target. Since risk factors and manifestations of CV disease are particularly common in gout (7), questions raised by the CARES trial findings are fundamentally important to clinical practice. From our perspective as rheumatologist gout researchers, we recap the original purpose of the CARES trial, evaluate the study results, and cite and discuss other relevant recent and ongoing trials. We also examine the potential ramifications of the CARES trial results for clinical practice.
Why was the CARES trial done?
The febuxostat CV safety issue originated from concerns about potential CV signals in the Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects (APEX) (8) , the Febuxostat versus Allopurinol Controlled Trial (FACT) (9) , a phase II trial (10) , and 2 long-term extension studies (11, 12) . Specifically, there was a numerical imbalance in the rate of CV events, with the group of patients who received febuxostat experiencing a higher number of events than those who received allopurinol or placebo. However, definitive conclusions could not be drawn from these earlier trials (13) . The numbers of events were too small to make meaningful inferences, no dose response was noted, the long-term extension studies had a limited number of participants receiving active control allopurinol, and Antiplatelet Trialists Collaboration (APTC) events had been evaluated in a post hoc manner.
In a subsequent 6-month randomized controlled trial (RCT) of febuxostat compared to allopurinol in 2,269 participants (termed CONFIRMS), CV adverse events were prospectively defined by a 3-person committee that adjudicated the APTC events (14) . At baseline in CONFIRMS, comorbid conditions were common, including mild-to-moderate renal impairment in 65%, a history of diabetes in 13.8%, hyperlipidemia in 42%, and hypertension in 53% of the patients. Adjudicated CV event rates were 0% for febuxostat 40 mg, 0.4% for febuxostat 80 mg, and 0.4% for allopurinol (P = 0.41 for allopurinol versus febuxostat) (14) . No CV deaths occurred in either of the febuxostat groups, and 2 CV deaths occurred in the allopurinol group.
Subsequent to CONFIRMS, febuxostat was approved in 2009 by the FDA for the management of hyperuricemia in gout, but the FDA required the drug manufacturer to perform a postmarketing RCT of adequate size and duration to compare febuxostat and allopurinol for the risk of serious adverse CV events. Similarly, the European Medicines Agency requested a post-licensing CV safety study comparing febuxostat to allopurinol in gout, termed the Febuxostat versus Allopurinol Streamlined Trial (FAST). This RCT is ongoing in the UK and Denmark (15) . An ongoing RCT in Japan (Febuxostat for Cerebral and Cardiorenovascular Events Prevention Study [FREED] ) (16) is distinct, in large part, in that the study population consists of patients with asymptomatic hyperuricemia (Table 1) .
What did the CARES trial show?
The CARES trial was a very large, multicenter, double-blind, noninferiority RCT comparing febuxostat to allopurinol treatment in patients with gout and established CV disease (2) . The primary end point was a composite of major adverse CV events (MACEs): CV death, nonfatal myocardial infarction (MI), nonfatal stroke, and unstable angina with urgent revascularization (Table 1) . Investigators determined sample size based on a noninferiority upper margin of 1.3, with the plan being to accrue 624 MACEs (17) . CARES subjects were randomized 1:1 to receive febuxostat 40 mg/day or allopurinol stratified on baseline renal function. The febuxostat dose was increased to 80 mg/day if serum urate concentration was >6 mg/dl at the week 2 study visit. The starting dose of allopurinol was dependent on renal function, and allopurinol dose escalation, based on reaching a target serum urate level of <6 mg/dl, was implemented in 100 mg/day increments monthly over the first 10 weeks to a maximum dose of 600 mg daily (400 mg daily in those with an estimated creatinine clearance of 30 to <60 ml/minute). Gout flare prophylaxis was provided for the first 6 months, preferentially with colchicine. Naproxen, other nonsteroidal antiinflammatory drugs (NSAIDs), and prednisone were permissible alternatives. The CARES trial followed up 6,190 randomized participants, documenting a total of 656 primary end points (2) . The median duration of exposure was comparable for febuxostat and allopurinol (728 versus 719 days, respectively), as was the duration of follow-up (968 versus 942 days, respectively). The investigators reported no increased risk related to febuxostat compared with allopurinol for the primary end point (hazard ratio [ , with all-cause mortality mainly due to CV mortality (Table 1) . Sudden cardiac death, the most common cause of CV death in both groups, occurred in 2.7% of the patients receiving febuxostat and 1.8% of the patients receiving allopurinol. The risk of CV death occurring during treatment or within 30 days after discontinuation of treatment was higher among those receiving febuxostat than those receiving allopurinol.
Gout flare rates over the study period were similar in the 2 groups in the CARES trial (2) . Although more participants in the febuxostat group had serum urate levels <5 mg/dl, the rates of participants achieving the serum urate treatment target of <6 mg/dl was similar between the 2 groups at all time points after 2 weeks. Below, we summarize key aspects of the CARES trial, and uncertainties from the trial results (Table 2) .
What are the strengths of the CARES trial design?
The CARES trial was double-blinded and randomized, with a state-of-the-art adjudication process for relevant CV disease end points. As such, it was designed to be free from confounding, performance bias, and detection bias, which are strengths compared to multiple prior observational studies of XOIs and CV disease in gout (18) (19) (20) (21) (22) . The CARES trial enrolled a relevant study population (i.e., people with gout and established CV disease), and investigators were able to observe a sufficient number of relevant CV and mortality events during the study period. Moreover, the direct comparison of allopurinol and febuxostat dose titration, including allopurinol dosing to >300 mg/day even in those with moderate renal impairment, and use of initial gout flare prophylaxis, preferably with colchicine rather than NSAIDs, to diminish systemic inflammation due to gout flares, were noteworthy in the CARES trial (2) . NSAIDs may have substantial CV event risk, particularly in people with established CV disease (23) . Moreover, in prespecified subgroup analyses, taking NSAIDs and not taking low-dose aspirin during the study were associated with a significantly elevated risk ratio for CV mortality in CARES (2).
What uncertainties arise from the results of the CARES trial? Impact of high rates of discontinuation and loss to follow-up. In the CARES trial, 57% of the participants discontinued treatment prematurely and 45% were lost to follow-up regardless of their treatment status, though the rates were similar between the 2 groups. These findings are applicable to clinical practice, since rates of long-term continuation of ULT are low (24) . However, from an experimental perspective, premature discontinuation of treatment assignment would generally bias safety signals toward the null. This could in turn threaten the validity of the results of the CARES trial primary end point, the risk of MACE composite end points. Furthermore, although the rates of loss to followup were similar between the 2 groups and the measured characteristics did not appear to be associated with loss to follow-up, it is conceivable that participants who (2) . These concerns appear to call for assessments of the potential impact of the high rate of loss to follow-up, to quantify the level of threat to the validity of primary as well as secondary end point results.
Lack of data on the temporal course and severity of gout flares. In theory, the intense inflammation pathophysiology of gout flares, with potential for associated prothrombotic status, and acute pain-related stress responses could have an impact on CV mortality. However, we do not know if there were undefined differences in the temporal course and severity of gout flares between the febuxostat and allopurinol groups in the CARES trial.
Questions regarding the biologic plausibility of the CARES trial results. Xanthine oxidoreductase and excess soluble urate, the joint targets of XOI treatment, can exert noxious effects in the vasculature and other tissues (25) (26) (27) (28) . Hence, the CARES trial leaves us with more questions than answers with respect to XOI effects on CV mortality. Xanthine oxidoreductase has wide tissue expression, can be released into the circulation, and binds the surface of endothelial cells (25) . XOI drugs directly reduce superoxide generation by the oxidized state of the enzyme, and limit oxidative stress and alter nitric oxide-redox balance, endothelial cell and mononuclear phagocyte activation, and inflammation in vitro and in vivo (25) (26) (27) (28) . Furthermore, XOI treatment inhibits experimental atherogenesis in vivo in mice (27) .
With respect to pharmacologic lowering of serum urate levels, a large body of in vitro and in vivo evidence supports the notion of proinflammatory effects, and toxic effects in the vasculature, of high levels of soluble urate (28) . These collective findings are buttressed by many human observational studies that have shown an association between elevated serum urate levels and CV disease event risk, all-cause mortality, and congestive heart failure (18) (19) (20) (21) (22) . On the other hand, Mendelian randomization analysis, though possessing a variety of limitations, has not supported the concept that urate lowering lowers the risk of CV disease (29) . To date, studies of the treatment of hyperuricemia in humans, including use of XOIs, and assessment of CV disease, are inconclusive (22, 23, 28) .
It remains possible that allopurinol may have beneficial effects on CV mortality, and also that the higher observed CV mortality rates in the febuxostat group in the CARES trial could have been similar to background rates. However, this hypothesis has not been directly tested in an RCT, and would be ethically challenging to address in a long-term RCT in patients with gout. We also note that in a biologic sense, the differences in the findings between fatal and nonfatal CV end points in the CARES trial (2) were unexpected and difficult to explain. For example, only 37 of the 234 CV deaths and 63 of the 442 all-cause deaths occurred in patients receiving study drugs, meaning that 85% of these deaths occurred when patients were not receiving study drugs (2) . In additional analyses, the investigators reported that 103 CV-related deaths and 164 all-cause deaths occurred while patients were receiving treatment or within 30 days after discontinuation of treatment. It is unclear why~23-28% of CVrelated and all-cause deaths occurred within 30 days after treatment discontinuation in the CARES trial.
Subtle differences in allopurinol and febuxostat need to be considered when positing biologic explanations for differing CV mortality results in the CARES trial. In this regard, febuxostat is a selective XOI, whereas the purine-like backbone of allopurinol and its active metabolite oxypurinol allow them to act as substrates for several enzymes involved in purine and pyrimidine metabolism, leading to the generation of a variety of ribonucleotides (30) . It is possible that the biologic effects of such ribonucleotides, and other intracellular actions of allopurinol and oxypurinol on purine and pyrimidine metabolism, could account for the effects of allopurinol on CV disease distinct from those of febuxostat in the CARES trial (30) , and possibly other RCTs (18) .
What would the differences in mortality be for either XOI drug compared to a non-XOI ULT control group or to placebo? Although the CARES trial addressed comparative safety between 2 XOIs, the results lead to new questions regarding how the mortality signal with either XOI agent would have compared to no ULT use (e.g., placebo) or to use of a non-XOI, urate-lowering agent such as a uricosuric agent. From a clinical trials design perspective, lack of a placebo was entirely appropriate, noting that allopurinol is the most widely used ULT agent, and a placebo arm would have been considered unethical for a long-term study in gout. However, the lack of placebo limits our ability to determine whether the mortality results of the CARES study are due to beneficial effects of allopurinol or deleterious effects of febuxostat. With respect to uricosuric ULT, a large observational study using Medicare data compared CV risk for allopurinol and probenecid (7) . Those with gout who initiated treatment with probenecid had a lower risk of hospitalization for MI or stroke compared with allopurinol initiators (HR 0.80 [95% CI 0.69-0.93]), with consistent results regardless of baseline chronic kidney disease or CV status (7). However, without performance of a prospective RCT with similar design features to the CARES trial, including assessment of serum urate lowering and gout flares, the Medicare study results cannot be compared to the results of the CARES trial.
Where do we go from here in current clinical practice?
Despite the aforementioned uncertainties related to the CARES study, the FDA public safety alert appears justified, and is likely to have a substantial impact on clinical practice. Specifically, clinicians and patients must take notice of the new, major findings of the CARES trial of increased risk of CV mortality by 34% and all-cause mortality by 22% with febuxostat compared with allopurinol. If we take at face value the point estimates reported in the CARES trial, febuxostat, compared to allopurinol, is calculated to have a number needed to harm of 91 for CV deaths and 71 for all-cause deaths among patients with gout and established CV disease over 2.7 years.
The ongoing European and Japanese febuxostat trials with CV end points (Table 1 ) may provide more clarity, which may lead regulatory agencies to take more definitive action than the current warning about the CV risk of febuxostat. Results of a large-scale trial (the ALL-HEART Study) are also awaited to assess potential allopurinol CV end point and mortality benefits in subjects without gout. In that study, allopurinol 600 mg/day is added to therapeutic regimens for patients with ischemic heart disease (31). The ongoing VA STOP GOUT comparative effectiveness RCT of allopurinol versus febuxostat does not appear likely to meaningfully impact the interpretation of the CARES results, since gout flare rate is the primary end point of VA STOP GOUT, and the study is not specifically powered to evaluate CV event risk (32) .
Ways in which we believe the new CARES trial results and FDA alert affect clinical practice are summarized in Table 3 . Patients are likely to ask the practicing clinician questions, including the following. Should I continue my febuxostat? Does taking febuxostat increase my risk of myocardial infarction? Finally, what are the alternatives to febuxostat? In this era of shared medical decision-making, it is advisable to discuss with patients the comparative CV mortality risks of allopurinol and febuxostat, and other safety risks of allopurinol, febuxostat, and uricosuric agents, such as the risks of side effects from severe drug hypersensitivity and drugdrug interactions, and renal adverse events including urolithiasis. The decisions made are based on the best available information and the personal values and preferences of each patient.
Clearly, both clinicians and patients should bear in mind that the CARES trial does not prove that taking febuxostat raises CV mortality risk in gout. Instead, the data suggest greater mortality risk with febuxostat than allopurinol in patients with preexisting CV disease. In this light, the CARES trial results do not support first-line use of febuxostat in ULT. The results also raise new questions regarding febuxostat placement at various pharmacologic ULT decision tree branches, since there are several efficacious first-line and secondline options other than febuxostat (Table 3) . For those clinical situations where febuxostat may be the most effective, or in a few scenarios, the only effective oral ULT option appropriate to use, engaging in shared medical decision-making helps patients make informed decisions about the risks and benefits of initiating and maintaining different therapy options.
All 4 recent major rheumatology society gout management guidelines have recommended febuxostat as a ULT option (3) (4) (5) (6) . In our opinion, systematic updates of gout ULT management guidelines by relevant professional organizations, employing appropriate committee processes and methodologies, are now needed to help guide decision-making on febuxostat and alternatives in oral pharmacologic ULT. This need arises from more than the new CARES study data and associated FDA safety alert. First, there are new data, from other RCTs, that support the efficacy of treat-tourate target pharmacologic ULT strategies for clinically and structurally meaningful end points in gout (33, 34) . Second, we note that the efficacy data for serum urate lowering, and the gout flares end points, were close between dose-titrated allopurinol and febuxostat in the CARES trial (2) . Third, more evidence now exists to support allopurinol as a relatively safe urate-lowering drug when risk factors for allopurinol hypersensitivity syndrome are taken into appropriate consideration (35) . Fourth, there is increased evidence of clinical efficacy and safety of allopurinol dose escalation in gout, commonly reaching doses >300 mg/day, and operable in the subset of patients with stage 3 chronic kidney disease (31, (36) (37) (38) . Fifth, allopurinol dose escalation was effective in the majority of patients with gout in a recent RCT (34) . Last, uricosuric monotherapy, and the combinations of allopurinol with certain uricosuric agents (e.g., probenecid or lesinurad), also are effective in many patients (3) (4) (5) (6) 39, 40) .
Conclusions
The newly published signal for increased CV and all-cause mortality with febuxostat compared with allopurinol in patients with gout in the CARES trial, and the associated FDA public safety alert, arose from a large and well-designed RCT powered to study CV events. There remain several uncertainties about the CARES trial findings. We await results of further ongoing RCTs, and there is the potential for further regulatory action. In the interim, the CARES trial does not support first-line use of febuxostat in ULT, and raises new questions regarding where febuxostat placement should be at different branches in the oral pharmacologic ULT decision tree for gout. New evidence has emerged in recent years of the efficacy of alternative options in many patients with gout, such as allopurinol dose escalation and the combination of allopurinol with uricosuric therapy. Moreover, uricosuric therapy remains a viable ULT option in many. Timely updates are now needed for gout ULT management guidelines by relevant professional organizations, using appropriate committee processes and methodologies.
